P Pharming Group NV
P
Gesloten
1.1 -2.57
Overzicht
Wijziging aandelenprijs
24u
Min
1.096
Max
1.133
Inkomsten | -10M -5.1M |
|---|---|
Verkoop | -36M 71M |
K/W Sectorgemiddelde | 55.3 51.415 |
EPS | 0.01 |
Winstmarge | -7.196 |
Werknemers | 407 |
EBITDA | -4.8M -2.1M |
Volgende Winsten | 30 jul 2026 |
|---|
Marktkapitalisatie | -227M 781M |
|---|---|
Vorige openingsprijs | 3.67 |
Vorige sluitingsprijs | 1.1 |
Pharming Group NV Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Pharming Group NV Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
